^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    VC004

    i
    Other names: VC004, VC 004, VC-004
    Associations

    News

    Trials
    Company:
    Jiangsu Vcare Pharma
    Drug class:
    pan-TRK inhibitor
    Related drugs:
    Associations

    News

    Trials
    18d
    Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors (clinicaltrials.gov)
    P3, N=54, Not yet recruiting, Jiangsu vcare pharmaceutical technology co., LTD
    New P3 trial
    |
    VC004
    1m
    A Clinical Trial to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects (clinicaltrials.gov)
    P1, N=56, Not yet recruiting, Jiangsu vcare pharmaceutical technology co., LTD
    New P1 trial
    |
    itraconazole • VC004 • rifampicin
    3ms
    Food Effect and Relative Bioavailability Study of VC004 Capsules in Healthy Adult Subjects (clinicaltrials.gov)
    P1, N=84, Completed, Jiangsu vcare pharmaceutical technology co., LTD | Not yet recruiting --> Completed | Trial completion date: Dec 2024 --> Aug 2024 | Trial primary completion date: Dec 2024 --> Aug 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    VC004
    4ms
    Food Effect and Relative Bioavailability Study of VC004 Capsules in Healthy Adult Subjects (clinicaltrials.gov)
    P1, N=84, Not yet recruiting, Jiangsu vcare pharmaceutical technology co., LTD
    New P1 trial
    |
    VC004
    10ms
    ETV6::NTRK3 gene fusion in a patient with metastatic lung atypical carcinoid successfully treated with repotrectinib: A case report. (PubMed, Lung Cancer)
    To the best of our knowledge, we reported the first case demonstrating anti-tumor activity of repotrectinib in a patient with AC carring an ETV6-NTRK3 gene fusion, indicating that repotrectinib may be an efficient therapeutic option for tumors with NTRK gene rearrangements.
    Clinical • Observational data • Retrospective data • Review • Clinical Trial,Phase I • Clinical Trial,Phase II • Journal • Metastases
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • ETV6 (ETS Variant Transcription Factor 6) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ETV6-NTRK3 fusion
    |
    everolimus • Augtyro (repotrectinib) • VC004
    11ms
    Food Effect on the Pharmacokinetics of VC004, a Tropomyosin Receptor Kinase Inhibitor: A Randomized Crossover Trial in Healthy Chinese Subjects. (PubMed, Clin Drug Investig)
    The intake of high calorie food decreased the absorption rate and increased the T of VC004, while the AUC values were similar in both groups. No serious adverse event was reported. In conclusion, food does not alter the pharmacokinetics and safety profile of VC004 in a clinically meaningful manner.
    PK/PD data • Journal
    |
    NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK positive • NTRK fusion
    |
    VC004